Yorba Linda, CA, August 25, 2015 --(PR.com
)-- DaVinci Biosciences, LLC, a company committed to improving the quality of life for those suffering from degenerative diseases, announced today that the Vice President of Research and Development, Rafael Gonzalez’s, paper “Mesenchymal Stem Cells for the Treatment of Arthritis” has been published in the book Anti-Aging Therapeutics, Volume 17 on pages 87-92 (Chapter 8).
Arthritis affects 37 million U.S. citizens, and it is estimated that this figure will rise to 67 million citizens by 2030. At present, there is no cure. However, there is an abundance of research suggesting that mesenchymal stem cells may provide us with a treatment for this disease. Indeed, clinical studies have shown that mesenchymal stem cells are both safe and effective at repairing cartilage and improving both pain and function. They are the stem cells of choice because they are multipotent, they have immunomodulatory and anti-inflammatory properties and provide trophic support. This entry offers a brief introduction into the use of mesenchymal cells to treat arthritis.
“I am honored to have been published in this book and to share my findings,” stated Dr. Rafael Gonzalez. Dr. Gonzalez hopes this scientific entry will spark more interest in the use of mesenchymal stem cell for the treatment of arthritis.
About DaVinci Biosciences LLC
DaVinci Biosciences, LLC is a cellular biology based company dedicated to improving the quality of life for individuals suffering from degenerative diseases and injuries. Through responsible research and development, DaVinci strives to be innovative leaders in biotechnology and regenerative medicine; renowned worldwide for their scientific and medical achievements and contributions to the health and well-being of communities. DaVinci Biosciences is also the parent company to DV Biologics, LLC., which is a leading global supplier of human primary cells and cell-derived products. DV Biologics manufactures the highest quality biological tools for use in academic institutions and pharmaceutical laboratories engaging in cell and drug based discovery and development. DV Biologics offers normal, human-derived primary cells and cell lines for research, genomic and proteomic biological tools, and a line of disease-specific primary cells and cell lines for the most accurate study of a particular disease profile. All of DV Biologics’ products are validated under the strictest quality assurance and control parameters, providing customers with reliable, guaranteed quality products for reproducible results.
DaVinci Biosciences and DV Biologics are headquartered in Yorba Linda, California.